2015 Q3 Form 10-Q Financial Statement
#000114420415067349 Filed on November 23, 2015
Income Statement
| Concept | 2015 Q3 | 2014 Q3 |
|---|---|---|
| Revenue | $0.00 | |
| YoY Change | ||
| Cost Of Revenue | $0.00 | |
| YoY Change | ||
| Gross Profit | $0.00 | |
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | ||
| YoY Change | ||
| % of Gross Profit | ||
| Research & Development | $0.00 | |
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | ||
| YoY Change | ||
| % of Gross Profit | ||
| Operating Expenses | $848.1K | $18.42K |
| YoY Change | 4505.13% | -52.67% |
| Operating Profit | -$18.42K | |
| YoY Change | -52.67% | |
| Interest Expense | $1.205K | $0.00 |
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | $1.205K | $0.00 |
| YoY Change | ||
| Pretax Income | -$45.43K | |
| YoY Change | 16.76% | |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$849.3K | -$18.42K |
| YoY Change | 4511.68% | -52.67% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | ||
| COMMON SHARES | ||
| Basic Shares Outstanding | 44.53M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2015 Q3 | 2014 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | ||
| YoY Change | ||
| Cash & Equivalents | ||
| Short-Term Investments | ||
| Other Short-Term Assets | ||
| YoY Change | ||
| Inventory | $0.00 | |
| Prepaid Expenses | $0.00 | |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $3.905K | $8.150K |
| YoY Change | -52.09% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | ||
| YoY Change | ||
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | ||
| YoY Change | ||
| Total Long-Term Assets | $0.00 | $0.00 |
| YoY Change | ||
| TOTAL ASSETS | ||
| Total Short-Term Assets | $3.905K | $8.150K |
| Total Long-Term Assets | $0.00 | $0.00 |
| Total Assets | $3.905K | $8.150K |
| YoY Change | -52.09% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $122.6K | |
| YoY Change | ||
| Accrued Expenses | ||
| YoY Change | ||
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | ||
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $122.6K | |
| YoY Change | ||
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | ||
| YoY Change | ||
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | ||
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $122.6K | |
| Total Long-Term Liabilities | ||
| Total Liabilities | $951.6K | $122.6K |
| YoY Change | 676.07% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$2.055M | -$887.3K |
| YoY Change | 131.66% | |
| Common Stock | $4.236K | $775.00 |
| YoY Change | 446.58% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$947.7K | $0.00 |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $3.905K | $8.150K |
| YoY Change | -52.09% |
Cashflow Statement
| Concept | 2015 Q3 | 2014 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$849.3K | -$18.42K |
| YoY Change | 4511.68% | -52.67% |
| Depreciation, Depletion And Amortization | ||
| YoY Change | ||
| Cash From Operating Activities | ||
| YoY Change | ||
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | ||
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $100.0K | $0.00 |
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | ||
| YoY Change | ||
| NET CHANGE | ||
| Cash From Operating Activities | ||
| Cash From Investing Activities | ||
| Cash From Financing Activities | ||
| Net Change In Cash | ||
| YoY Change | ||
| FREE CASH FLOW | ||
| Cash From Operating Activities | ||
| Capital Expenditures | ||
| Free Cash Flow | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2015Q3 | us-gaap |
Assets Current
AssetsCurrent
|
3905 | USD |
| CY2015Q3 | us-gaap |
Debt Instrument Fee Amount
DebtInstrumentFeeAmount
|
60000 | USD |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
20881 | USD |
| CY2015Q3 | us-gaap |
Assets
Assets
|
3905 | USD |
| CY2014Q4 | us-gaap |
Assets
Assets
|
20881 | USD |
| CY2015Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
510493 | USD |
| CY2014Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
173801 | USD |
| CY2015Q3 | us-gaap |
Liabilities
Liabilities
|
951581 | USD |
| CY2014Q4 | us-gaap |
Liabilities
Liabilities
|
277010 | USD |
| CY2015Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
4236 | USD |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2400 | USD |
| CY2015Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
963506 | USD |
| CY2014Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
-674 | USD |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-257805 | USD |
| CY2015Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-2055470 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-256129 | USD |
| CY2015Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-947676 | USD |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
20881 | USD |
| CY2015Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
3905 | USD |
| CY2015Q3 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
0 | USD |
| CY2014Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
20000 | USD |
| CY2015Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
0 | USD |
| CY2014Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
50000 | USD |
| CY2015Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2015Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
42358750 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
24000000 | shares |
| CY2015Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
42358750 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
24000000 | shares |
| CY2015Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
848127 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
1792805 | USD | |
| CY2015Q3 | us-gaap |
Interest Expense
InterestExpense
|
1205 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
4860 | USD | |
| CY2015Q3 | us-gaap |
Other Expenses
OtherExpenses
|
1205 | USD |
| us-gaap |
Other Expenses
OtherExpenses
|
4860 | USD | |
| CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-849333 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-1797665 | USD | |
| CY2015Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.03 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.12 | ||
| CY2015Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
26437692 | shares |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
14812564 | shares | |
| CY2015Q3 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
848127 | USD |
| us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
1792805 | USD | |
| CY2015Q3 | mntm |
Common Stock To Be Issued
CommonStockToBeIssued
|
100000 | USD |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2015Q3 | us-gaap |
Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
|
423588 | USD |
| CY2014Q4 | us-gaap |
Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
|
0 | USD |
| CY2015Q3 | us-gaap |
Convertible Debt
ConvertibleDebt
|
0 | USD |
| CY2014Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
53209 | USD |
| CY2015Q3 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
140097 | USD |
| CY2014Q4 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
0 | USD |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 1 – Nature of the Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Mount Tam Biotechnologies, Inc. (“Mount Tam” or the “Company”) was incorporated on August 13, 2014 (date of inception) as a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Nevada corporation</font>. On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">August 13, 2014</font>, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,000,000</font> shares of common stock, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> par value (“Common Stock”), for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">900</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 27pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On August 13, 2015, the Company entered into an Agreement and Plan of Merger (the “<u>Merger Agreement</u>”) with TabacaleraYsidron, Inc., a Nevada corporation (“<u>Parent</u>” and “Surviving Corporation”). Pursuant to the Merger Agreement, the boards of directors of Parent and deem it advisable and in the best interests of their respective companies and shareholders that Mount Tam be merged with and into Parent, with Parent remaining as the surviving corporation under the name “Mount TAM Biotechnologies, Inc.” </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Prior to and as a requirement of the Merger, TabacaleraYsidron, Inc., cancelled <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 28,175,000</font> shares of common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On August 13, 2015, the closing date of the Merger, the separate existence of Mount Tam, the prior private company, shall cease, and Parent shall be the surviving corporation under the name “Mount TAM Biotechnologies, Inc.” and shall be governed by the laws of the State of <u> Nevada</u>. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Merger was treated as a reverse acquisition of the Company, a public shell company, for financial accounting and reporting purposes. As such, Mount Tam was treated as the acquirer for accounting and financial reporting purposes while the Company is treated as the acquired entity for accounting and financial reporting purposes. $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">51,248</font> account payable and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,500</font> note payable of the acquired entity have been brought forward at their book value and no goodwill has been recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Mount Tam is an early-stage science and technology company and is primarily engaged in the development of bio-pharmaceuticals to treat autoimmune diseases. The Company intends to optimize and bring to market a portfolio of products focused on improving the health and well being of people afflicted with autoimmune diseases. Prior to the Merger, TabacaleraYsidron, Inc., was non-operating public shell company with nominal operations and nominal assets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY:Times New Roman, Times, Serif">To meet its business objectives, the Company has formed a strategic partnership with the Buck Institute for Research on Aging (“Buck Institute”), an independent research facility focused on understanding the connection between aging and chronic disease. As part of the partnership, the Company has signed an exclusive worldwide licensing and collaboration agreement with the Buck Institute that includes many of the Buck Institute’s intangible research and development assets in the area of autoimmune disorders. The initial focus of the Company’s research and development efforts will be a pre-clinical stage compound for the treatment and diagnosis of systemic lupus erythematosus, a common form of lupus. The Company has not produced any revenues from the intangible research and development assets it acquired from Buck Institute and the Company has not commenced its planned principal operations</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The production and marketing of the Company’s products and its ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any drug developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the Food and Drug Administration under the Food, Drug and Cosmetic Act. In addition, the Company’s success will depend in part on its ability to obtain and maintain patents, exploit its product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2014-08-13 | ||
| CY2015Q3 | mntm |
Working Capital Deficit
WorkingCapitalDeficit
|
947676 | USD |
| CY2015Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
16358750 | shares |
| CY2015Q3 | us-gaap |
Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
|
24000000 | shares |
| CY2015Q3 | us-gaap |
Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
|
2000000 | shares |
| CY2015Q3 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
1000000 | USD |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P9Y11M23D | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure | |
| CY2015Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
15404 | USD |
| CY2015Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
311741 | USD |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y10M24D | ||
| CY2014Q4 | us-gaap |
Noninterest Expense Investment Advisory Fees
NoninterestExpenseInvestmentAdvisoryFees
|
10000 | USD |
| CY2015Q3 | mntm |
Convertible Notes Price Per Share
ConvertibleNotesPricePerShare
|
0.50 | |
| dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
Nevada corporation | ||
| CY2015Q3 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
17500 | USD |
| CY2014Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
0 | USD |
| CY2014Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
0 | USD |
| CY2014Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
18417 | USD |
| CY2014Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
18417 | USD |
| CY2014Q3 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
18417 | USD |
| CY2014Q3 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| CY2014Q3 | us-gaap |
Other Expenses
OtherExpenses
|
0 | USD |
| CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18417 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
34861 | USD | |
| CY2015Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
100000 | USD |
| CY2015Q3 | us-gaap |
Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
|
45 | USD |
| CY2014Q4 | us-gaap |
Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
|
50 | USD |
| CY2015Q3 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.035 | pure |
| us-gaap |
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
|
966255 | shares | |
| CY2015Q3 | us-gaap |
Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
|
40000 | USD |
| us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
34861 | USD | |
| CY2014Q3 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
0 | USD |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
40000 | USD | |
| CY2014Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
0 | USD |
| us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
20000 | USD | |
| CY2014Q3 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
0 | USD |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
285444 | USD | |
| CY2014Q3 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-18417 | USD |
| us-gaap |
Increase Decrease In Due To Employees Current
IncreaseDecreaseInDueToEmployeesCurrent
|
423588 | USD | |
| CY2014Q3 | us-gaap |
Increase Decrease In Due To Employees Current
IncreaseDecreaseInDueToEmployeesCurrent
|
0 | USD |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-993772 | USD | |
| CY2014Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
0 | USD |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
0 | USD | |
| CY2014Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
0 | USD |
| us-gaap |
Proceeds From Loans
ProceedsFromLoans
|
896791 | USD | |
| CY2014Q3 | us-gaap |
Proceeds From Loans
ProceedsFromLoans
|
0 | USD |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
100005 | USD | |
| CY2014Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
996796 | USD | |
| CY2014Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD |
| us-gaap |
Cash Period Increase Decrease
CashPeriodIncreaseDecrease
|
3024 | USD | |
| CY2014Q3 | us-gaap |
Cash Period Increase Decrease
CashPeriodIncreaseDecrease
|
0 | USD |
| CY2014Q3 | us-gaap |
Cash
Cash
|
0 | USD |
| CY2014Q3 | us-gaap |
Cash
Cash
|
0 | USD |
| us-gaap |
Interest Paid
InterestPaid
|
0 | USD | |
| CY2014Q3 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | USD | |
| CY2014Q3 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | USD |
| us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
30000 | USD | |
| CY2014Q3 | us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
0 | USD |
| mntm |
Common Stock Issued For Reverse Merger Recapitalization
CommonStockIssuedForReverseMergerRecapitalization
|
68748 | USD | |
| CY2014Q3 | mntm |
Common Stock Issued For Reverse Merger Recapitalization
CommonStockIssuedForReverseMergerRecapitalization
|
0 | USD |
| us-gaap |
Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
|
1000000 | USD | |
| CY2014Q3 | us-gaap |
Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
|
0 | USD |
| us-gaap |
Stock Issued1
StockIssued1
|
97 | USD | |
| CY2014Q3 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
